Centogene and Lifera kick-off joint venture
Multi-omics diagnostics specialist Centogene NV has received 30m to form a joint venture with PIF-owned pharmaceutical company Lifera in Saudi-Arabia.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
Entries by Thomas Gabrielczyk
Astraveus SAS bags 16.5m in seed financing
/in News/by Thomas GabrielczykFrench cell and gene therapy manufacturing specialist Astraveus SAS had raises 16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.
New BIOTECH insight newsletter out
/in News/by Thomas GabrielczykBreaking news from biotechnology and the German stock market are in the focus of the new issue of BIOTECH Insight, the newsletter of Deutsche Börse AG.
Santhera licences vamorolone rights to Catalyst Pharmaceuticals
/in News/by Thomas GabrielczykSanthera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
BioSenic halts ALLOB development
/in News/by Thomas GabrielczykBioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.
Neogap fully takes over TCER Oncology shares
/in News/by Thomas GabrielczykSwedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.
Antibody provides broad protection vs hantaviruses
/in News/by Thomas GabrielczykAn international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.
Syncona launches new gene therapy company Beacon Therapeutics
/in News/by Thomas GabrielczykSyncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.
Roche to file MAA for eculizumab competitor
/in News/by Thomas GabrielczykRoche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.
CGT Catapult expanding with Scotch facility
/in News/by Thomas GabrielczykThe world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh.